A groundbreaking genome-edited immune cell therapy transforms treatment for T-cell leukaemia

At just 13 years old, Alyssa Tapley lay in a hospital bed at Great Ormond Street, battling T-cell acute lymphoblastic leukaemia (T-ALL), a diagnosis that heralded a tumultuous fight for survival. After enduring standard treatments that failed to yield results, her family was left grappling with despair. Then, in a moment that felt like a lifeline, Alyssa became the first patient in the world to receive BE-CAR7, a revolutionary treatment using genome-edited immune cells developed by researchers at University College London (UCL) and GOSH. “I thought my life was over,” Alyssa recalled, her eyes wide with disbelief as she spoke about the drastic transformation her life has undergone since her treatment.

This pioneering gene therapy, which utilizes advanced base-editing technology, has shown staggering promise in treating a once-untreatable type of blood cancer. Base-editing, an advanced variant of CRISPR, allows scientists to make precise changes within the DNA of living cells. According to Professor Waseem Qasim, who led the initiative, “Previously, we could only dream of such precision. Now, we have the power to edit genes at a level that transforms patient outcomes.”

The Breakthrough Study

In a clinical trial that has captured the attention of the medical community, results from the treatment have just been published in the New England Journal of Medicine. The findings reveal a remarkable response among participants:

• 82% of patients achieved very deep remissions, enabling them to proceed to stem cell transplant without disease.
• 64% remain disease-free, with some patients now three years off treatment.
• Anticipated side effects, including low blood counts and cytokine release syndrome, were manageable, with the highest risk stemming from viral infections during recovery.

“While traditional T-cell therapies have made strides, taming a cancer arising from T-cells themselves has been challenging,” said Dr. Rob Chiesa, a bone marrow transplant consultant involved in the study. “This research not only provides hope but represents a transformative direction in treatment.”

Alyssa’s Journey

Alyssa’s journey, while illuminating, also highlights the complexities and uncertainties every participant faced. Initially misdiagnosed with common ailments, her family’s hopes dwindled as conventional therapies failed. Yet, the introduction of BE-CAR7 changed everything. “I went from wondering if I would ever grow up to living a normal life again. It’s just incredible,” Alyssa shared, smiling as she recounted the newfound freedom she relishes. From sailing to completing her Duke of Edinburgh Award, every milestone feels monumental, underlined by a gratitude her family now treasures.

Her father, James Tapley, spoke of the seismic shift from despair to hope. “We thought we might become a family of three. Now, we’re thriving—and it’s a miracle. We owe so much to the team at UCL and GOSH, who worked so tirelessly to bring this therapy to life.”

A Unique Approach to Cell Therapy

Unlike conventional CAR-T cell therapies, which modify immune cells to fight cancer, BE-CAR7 employs base-editing techniques to produce “universal” T-cells, negating the need for matching donor and patient cells. This approach sidesteps the typical challenges faced in cellular therapies. “The traditional method involves complex matching processes and risks of autoimmune responses,” explained Dr. Deborah Yallop, a haematologist. “With BE-CAR7, we’re simplifying that landscape.”

How Base-Editing Works

Using advanced CRISPR technology, scientists perform precise edits to the DNA of immune cells. The process can be distilled into four key steps:

• Removing existing T-cell receptors to create universal donors.
• Deleting the CD7 marker to prevent T-cells from attacking each other.
• Eliminating the CD52 marker to render the cells invisible to immunosuppressive drugs.
• Incorporating a chimeric antigen receptor (CAR) to target cancerous T-cells directly.

Once administered, these base-edited CAR T-cells seek out and destroy all T-cells producing the rogue cancer, providing hope for patients who, like Alyssa, previously faced bleak prognoses.

The Future of Gene Therapy

Looking forward, the researchers emphasize that while results have been promising, the journey is far from over. “This trial has been a significant step but also a reminder of the necessity for ongoing research and improvements,” Professor Qasim noted. “Outcomes can vary, and the experiences of patients like Alyssa serve as both an inspiration and a call to action.”

The trial, sponsored by GOSH and supported by several prestigious organizations, is now set to expand as Great Ormond Street Hospital Charity steps in to fund treatment for additional patients. “We are excited to extend this opportunity,” noted a spokesperson for the charity. “This therapy could change lives, and we are committed to ensuring as many patients as possible benefit from it.”

As Alyssa Tapley embraces her second chance at life, she stands as a beacon of hope and resilience—a living embodiment of the tremendous potential locked within the realm of gene therapy. “Every day feels like a gift,” she reflected, and her journey shines as a testament to the marvel of modern medicine, igniting hope for countless others battling similar fates.

Source: www.ucl.ac.uk